- Histone deacetylase inhibitors
Paul A. Marks, 2013, Molecular Oncology CrossRef - HDAC8: A Promising Therapeutic Target for Acute Myeloid Leukemia
Marco Spreafico et al, 2020, Frontiers in Cell and Developmental Biology CrossRef - Combining EGFR-TKI With SAHA Overcomes EGFR-TKI-Acquired Resistance by Reducing the Protective Autophagy in Non-Small Cell Lung Cancer
Peijun Cao et al, 2022, Frontiers in Chemistry CrossRef - HDAC8 as a target in drug discovery: Function, structure and design
Qianlong Zhao et al, 2024, European Journal of Medicinal Chemistry CrossRef - Metabolism and Epigenetic Interplay in Cancer: Regulation and Putative Therapeutic Targets
Vera Miranda-Gonçalves et al, 2018, Frontiers in Genetics CrossRef - Expression of HDAC8 indicates poor prognosis of esophageal squamous cell carcinoma and progression to advanced stage
Cheng Yufeng et al, 2019, International Journal of Cancer and Oncology CrossRef - Synthesis of N‐aminophalimides derived from α‐amino acids: Theoretical study to find them as HDAC8 inhibitors by docking simulations and in vitro assays
José Eduardo Guzmán Ramírez et al, 2023, Chemical Biology & Drug Design CrossRef - The Relationship between Histone Deacetylase (HDACs) and Gastric Cancer
珊 徐, 2020, Advances in Clinical Medicine CrossRef - Structure-Based Design and Synthesis of Novel Inhibitors Targeting HDAC8 from Schistosoma mansoni for the Treatment of Schistosomiasis
Tino Heimburg et al, 2016, Journal of Medicinal Chemistry CrossRef - A Review on the Anticancer Activity of Carbazole-based Tricyclic Compounds
Hua Zhang et al, 2024, Current Medicinal Chemistry CrossRef - Comprehensive Analysis of the Differential Expression and Prognostic Value of Histone Deacetylases in Glioma
Jinwei Li et al, 2022, Frontiers in Cell and Developmental Biology CrossRef - In silico identification of dual HDAC8 and MMP9 inhibitors by pharmacophore modeling, molecular docking, and molecular dynamics simulation studies for development of antitumour agent
Kakali Sarkar et al, 2024, Interactions CrossRef - Lysine Deacetylase Inhibitors in Parasites: Past, Present, and Future Perspectives
Gebremedhin S. Hailu et al, 2017, Journal of Medicinal Chemistry CrossRef - Cytotoxicity Mediated by Histone Deacetylase Inhibitors in Cancer Cells: Mechanisms and Potential Clinical Implications
David S. Schrump, 2009, Clinical Cancer Research CrossRef - Progress in the research of epigenetic regulators in cancer therapy
LongJiang DI et al, 2023, SCIENTIA SINICA Vitae CrossRef - Concept of histone deacetylases in cancer: Reflections on esophageal carcinogenesis and treatment
Dimitrios Schizas et al, 2018, World Journal of Gastroenterology CrossRef - Synergistic Effect of Epigenetic Inhibitors Decitabine and Suberoylanilide Hydroxamic Acid on Colorectal Cancer In vitro
Sonia Abou Najem et al, 2019, Current Molecular Pharmacology CrossRef - Epigenetic control of gene function in schistosomes: a source of therapeutic targets?
Alejandro Cabezas-Cruz et al, 2014, Frontiers in Genetics CrossRef - New synergistic combination therapy approaches with HDAC inhibitor quisinostat, cisplatin or PARP inhibitor talazoparib for urothelial carcinoma
Sarah Meneceur et al, 2024, Journal of Cellular and Molecular Medicine CrossRef - Histone Deacetylase Inhibitors as Therapeutic Interventions on Cervical Cancer Induced by Human Papillomavirus
Natália Lourenço de Freitas et al, 2021, Frontiers in Cell and Developmental Biology CrossRef - High Histone Deacetylase 2/3 Expression in Non-Functioning Pituitary Tumors
Wenxiu Zhao et al, 2022, Frontiers in Oncology CrossRef - Characterization of the HDAC1 Complex That Regulates the Sensitivity of Cancer Cells to Oxidative Stress
Takuya Kato et al, 2009, Cancer Research CrossRef - B7-H3-targeted Radioimmunotherapy of Human Cancer
Benjamin B. Kasten et al, 2020, Current Medicinal Chemistry CrossRef - Histone modification and histone modification-targeted anti-cancer drugs in breast cancer: Fundamentals and beyond
Jianwei Feng et al, 2022, Frontiers in Pharmacology CrossRef - Structure-Based Discovery of Selective Histone Deacetylase 8 Degraders with Potent Anticancer Activity
Jinbo Huang et al, 2023, Journal of Medicinal Chemistry CrossRef - Acetylation in Tumor Immune Evasion Regulation
Jun Lu et al, 2021, Frontiers in Pharmacology CrossRef - Epigenetic Modulators as Treatment Alternative to Diverse Types of Cancer
Jorseth Rodelo Gutiérrez et al, 2022, Current Medicinal Chemistry CrossRef - Down expression of lnc-BMP1-1 decreases that of Caveolin-1 is associated with the lung cancer susceptibility and cigarette smoking history
Xiaoxuan Ling et al, 2020, Aging CrossRef - Largazole is a Brain-Penetrant Class I HDAC Inhibitor with Extended Applicability to Glioblastoma and CNS Diseases
Fatma H. Al-Awadhi et al, 2020, ACS Chemical Neuroscience CrossRef - Expression of acetylated histones H3 and H4 and histone deacetylase enzymes HDAC1, HDAC2 and HDAC6 in simple mammary carcinomas of female dogs
Igor Luiz Salardani Senhorello et al, 2023, Frontiers in Genetics CrossRef - Genetic Segmentation and Targeted Therapeutics for Multiple Myeloma
Louis Williams et al, 2019, Oncology & Hematology Review (US) CrossRef - KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
Christian A. Hassig et al, 2008, Molecular Cancer Therapeutics CrossRef - Zinc Dependent Histone Deacetylase Inhibitors in Cancer Therapeutics: Recent Update
Faria Sultana et al, 2020, Current Medicinal Chemistry CrossRef - Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy
Tingting Liu et al, 2020, Journal of Medicinal Chemistry CrossRef